Published Special Issue
Expired Date:
Apr. 30, 2015
Order the Hard Copy
Special Issues
Expand the Popularity of Your Conference
Publish conference papers as a Special Issue
Send your Special Issue proposal to:
Submit Hot Topics
If you wish to order hard copies, please click here to know more information.
Home / Journals / Journal of Cancer Treatment and Research / MiRNAs Related with Cancer Drug Resistance
MiRNAs Related with Cancer Drug Resistance
Lead Guest Editor:
Sercan Ergün
Department of Medical Biology, Faculty of Medicine, Gaziantep University, Sahinbey, Gaziantep, Turkey
Guest Editors
Kaifee Arman
Department of Medical Biology, Faculty of Medicine, Gaziantep University
Gaziantep, Turkey
Chemotherapy is the preferred treatment for cancer treatment. However, a successful long-term use of chemotherapy is often prevented by the development of drug resistance. Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The anticancer drug resistance mechanisms have been extensively explored, yet have not been fully characterized. Recent works have underlined the involvement of noncoding RNAs in cancer development, with several studies regarding their possible involvement in the evolution of drug resistance. MiRNAs are negative regulators of protein coding genes. Recently, microRNA-122’s functions in breast cancer (BC) remain unknown. During last decades, microRNAs (miRNAs), a class of non-coding RNAs, have emerged as critical players in cancer pathogenesis and progression by modulating many pathological aspects related to tumor development, growth, metastasis, and drug resistance. More recently, accumulating evidence is revealing an important role of miRNAs in anticancer drug resistance and miRNA expression profiling can be correlated with the development of anticancer drug resistance. The micro-RNA-mediated form of drug resistance adds yet another mechanism of drug resistance. So, exploiting the emerging knowledge of miRNAs for the development of new human therapeutic applications for overcoming anticancer drug-resistance will be important. This special issue would include all miRNA involvements which lead to cancer drug resistance.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186